The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma

Pediatric Blood and Cancer

Volumn 61, Issue 8, 2014, Pages 1382-1386

  Rasper, Meybrit ^a   Jabar, Susanne ^a   Ranft, Andreas ^a   Jürgens, Heribert ^a   Amler, Susanne ^a   Dirksen, Uta ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Busulfan; Ewing sarcoma; High dose chemotherapy; Relapse; Treosulfan

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; TEMOZOLOMIDE; TOPOTECAN; TREOSULFAN;

ADOLESCENT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HIGH DOSE CHEMOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSED EWING SARCOMA; RETROSPECTIVE STUDY; SURVIVAL RATE;

BUSULFAN; EWING SARCOMA; HIGH-DOSE CHEMOTHERAPY; RELAPSE; TREOSULFAN;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES; SARCOMA, EWING; SURVIVAL RATE;

EID: 84901988085     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25042     Document Type: Article

References (20)

1. Dirksen U, Jürgens H. Approaching Ewing sarcoma. Future Oncol 2010; 6:1155-1162.
2. Leavey PJ, Collier AB. Ewing sarcoma: Prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008; 8:617-624.
3. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence an Survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549-553.
4. McTiernan AM, Cassoni AM, Driver D, et al. Improving outcomes after relapse in Ewing's sarcoma: Analysis of 114 patients from a single institution. Sarcoma 2006; 2006:83548.
5. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing tumors. J Clin Oncol 2005; 23:4354-43562.
6. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47:795-800.
7. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecanfor treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48:132-139.
8. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002; 94:561-569.
9. Grohar P, Helman J. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 2013; 137:216-224.
10. Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116:443-450.
11. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22-29.
12. Ladenstein R, Pötschger U, Le Delay MC, et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28:3284-3291.
13. Leavy PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) et first recurrence following multimodal therapy - a report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51:334-338.
14. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003; 14:1654-1659.
15. Bacci G, Longhi A, Ferrari S, et al. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur J Surg Oncol 2006; 32:974-979.
16. Thiel U, Wawer A, Wolf P, et al. No improvement of survival with reduced- versus high-intensity conditioning for allogenic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22:1614-1621.
17. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup Study EICESS. Ann Oncol 2000; 11:1451-1462.
18. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21:3072-3078.
19. Ferrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 2011; 22:1221-1227.
20. Jürgens H, Dirksen U, Jabar S, et al. Retrospective analysis of treatment-related toxicities and outcome in high-risk Ewing sarcoma patients receiving Treosulfan or Busulfan-based high-dose chemotherapy with autologous stem cell transplantation. J Cancer Res Clin Oncol 2012; 138:9.